MME SENEM TAN

Rhumatologue

📍 NANCY CEDEX (54)HospitalierRPPS 10100553816

✨ Profil synthétique

IA · 25/05/2026

MME SENEM TAN est une rhumatologue hospitalière à NANCY CEDEX. Ses publications sur PubMed couvrent des sujets tels que le lupus, les essais cliniques et les recommandations en rhumatologie. Elle a également publié des revues et des méta-analyses sur divers aspects de la rhumatologie, y compris l'économie de la santé.

Expertises présumées

Lupus érythémateux systémique
Essais cliniques en rhumatologie
Recommandations en rhumatologie
Revue de littérature médicale
Méta-analyse en rhumatologie
Économie de la santé en rhumatologie

Synthèse automatique à partir des sources publiques (HAL, OpenAlex, theses.fr, ClinicalTrials.gov, FAI²R, ANS). Pas une évaluation clinique. Le médecin peut corriger via son compte.

✨ Génération du profil synthétique IA en cours…

Lieu de consultation

CHRU NANCY - HOPITAL CENTRAL
29 AV DE LATTRE DE TASSIGNY CO 60034, 54035 NANCY CEDEX
☎ 0383858585Activité de soin et de pharmacie

Tarifs & secteur de conventionnement

Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).

📊 Comprendre le remboursement

Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.

Top publications · les plus citées

The impact of mitochondrial dysfunction on osteoarthritis cartilage: current insights and emerging mitochondria-targeted therapies

Bone research · 2025

📚 13 citations🎯 RCR 5.42🔓 Open Access📄 PDF gratuit ↗

Lire l'abstract Crossref ↓

Abstract Osteoarthritis (OA) is a degenerative joint disease associated with age, prominently marked by articular cartilage degradation. In OA cartilage, the pathological manifestations show elevated chondrocyte hypertrophy and apoptosis. The mitochondrion serves as key energy supporter in eukaryotic cells and is tightly linked to a myriad of diseases including OA. As age advances, mitochondrial function declines progressively, which leads to an imbalance in chondrocyte energy homeostasis, partially initiating the process of cartilage degeneration. Elevated oxidative stress, impaired mitophagy and mitochondrial dynamics jointly contribute to chondrocyte pathology, with mitochondrial DNA haplogroups, particularly haplogroup J, influencing OA progression. Therapeutic approaches directed at mitochondria have demonstrated remarkable efficacy in treating various diseases, with triphenylphosphonium (TPP) emerging as the most widely utilized molecule. Other strategies encompass Dequalinium (DQA), the Szeto-Schiller (SS) tetrapeptide family, the KLA peptide, and mitochondrial-penetrating peptides (MPP), etc. These molecules share common properties of lipophilicity and positive charge. Through various technological modifications, they are conjugated to nanocarriers, enabling targeted drug delivery to mitochondria. Therapeutic interventions targeting mitochondria offer a hopeful direction for OA treatment. In the future, mitochondria-targeted therapy is anticipated to improve the well-being of life for the majority of OA patients. This review summarizes the link between chondrocyte mitochondrial dysfunction and OA, as well as discusses promising mitochondria-targeted therapies and potential therapeutic compounds.

T Cell-Derived Apoptotic Extracellular Vesicles Ameliorate Bone Loss via CD39 and CD73-Mediated ATP Hydrolysis

International journal of nanomedicine · 2025

📚 10 citations🎯 RCR 4.17🔓 Open Access

(18)F-FDG-PET/MR imaging to monitor disease activity in large vessel vasculitis

Nature communications · 2024

📚 10 citations🎯 RCR 3.04Top 16% NIH🔓 Open Access📄 PDF gratuit ↗

Lire l'abstract Crossref ↓

AbstractDisease-monitoring in large vessel vasculitis (LVV) is challenging. Simultaneous18F-fluorodeoxyglucose positron emission tomography with magnetic resonance imaging (PET/MRI) provides functional assessment of vascular inflammation alongside high-definition structural imaging with a relatively low burden of radiation exposure. Here, we investigate the ability of PET/MRI to monitor LVV disease activity longitudinally in a prospective cohort of patients with active LVV. We demonstrate that both the PET and MRI components of the scan can distinguish active from inactive disease using established quantification methods. Using logistic-regression modelling of PET/MRI metrics, we devise a novel PET/MRI-specificVasculitisActivity usingMRPET (VAMP) score which is able to distinguish active from inactive disease with more accuracy than established methods and detects changes in disease activity longitudinally. These findings are evaluated in an independent validation cohort. Finally, PET/MRI improves clinicians’ assessment of LVV disease activity and confidence in disease management, as assessed via clinician survey. In summary, PET/MRI may be useful in tracking disease activity and assessing treatment-response in LVV. Based on our findings, larger, prospective studies assessing PET/MRI in LVV are now warranted.

Cookies & analyse de trafic

MME SENEM TAN

Pourquoi vous devez consulter ce praticien

Lieu de consultation

Tarifs & secteur de conventionnement

Prendre rendez-vous & contact

Top publications · les plus citées

Publications scientifiques (35) — classées par pathologie

Transversal12

Lupus4

Essai clinique3

Recommandations3

Revue / méta-analyse3

Revue générale3

Économie santé2

IA en rhumatologie2

Biomarqueurs / Auto-Ac1

Épidémiologie & registres1

Goutte1

Lombalgie1

Microbiote1

Vascularites1

Vascularites des gros vaisseaux1

Partager cette fiche